Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ASTX727 (standard dose)
2018-003942-18Phase 2Active
- Sponsor
- Taiho Oncology
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inqovi in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Taiho Oncology. Primary endpoint: Safety as measured by adverse events. Started Jun 2021; status: active.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2018-003942-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003942-18.